[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"healhty\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:healhty":26},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,17,0,[8,43,76,98,126,149,173,195,214,235,259,291,314,340,365,386,414],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":17,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":20,"targetDuration":4,"studyType":23,"phases":4,"briefSummary":24,"conditions":25,"keywords":27,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":31,"lastUpdatePostDateStruct":32,"startDateStruct":35,"completionDateStruct":37,"leadSponsor":39,"locationsCount":42},"100644858","validation-of-a-new-system-for-measuring-ventilation-and-co-production-100644858",false,"NCT07677241","Validation of a New System for Measuring Ventilation and CO₂ Production","Comparison of a New Gas Exchange Measurement System During Exercise With a Reference System","PAIRFS","Inclusion Criteria:\n\n* Male or female adults (aged ≥ 18 years).\n* Individuals affiliated with, or benefiting from, a health insurance or social security scheme.\n* Individuals capable of understanding and signing an informed consent form.\n* Individuals fluent in French.\n\nExclusion Criteria:\n\n* Current tobacco smoking.\n* Any cardiovascular, respiratory, or musculoskeletal condition that could impair the ability to perform a maximal exercise test.\n* Individuals unwilling or unable to provide written informed consent.\n* Individuals with hierarchical, family, or close personal relationships with the principal investigator.",true,"ALL","18 Years",{"count":21,"type":22},20,"ESTIMATED","OBSERVATIONAL","Gas exchange measurement systems are complex and require specialized facilities and expertise. As a result, access to these measurements remains limited, particularly in the field of sports performance. The aim of this validation study was to compare measurements obtained with a reference device and a new portable system.",[26],"Healhty",[28,29],"exercise","ventilatory measurement","NOT_YET_RECRUITING","2026-06-29",{"date":33,"type":34},"2026-06-30","ACTUAL",{"date":36,"type":22},"2026-07-30",{"date":38,"type":22},"2026-10-30",{"name":40,"class":41},"University Hospital, Grenoble","OTHER",1,{"id":44,"slug":45,"hasResults":11,"nctId":46,"briefTitle":47,"officialTitle":47,"acronym":48,"eligibilityCriteria":49,"healthyVolunteers":17,"sex":18,"minAge":50,"maxAge":4,"enrollmentInfo":51,"targetDuration":4,"studyType":53,"phases":54,"briefSummary":56,"conditions":57,"keywords":59,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":66,"lastUpdatePostDateStruct":67,"startDateStruct":69,"completionDateStruct":71,"leadSponsor":73,"locationsCount":75},"100643540","validation-of-a-remediation-method-for-memory-impairments-through-motor-encoding-in-patients-with-alzheimers-disease-100643540","NCT07632755","Validation of a Remediation Method for Memory Impairments Through Motor Encoding in Patients With Alzheimer's Disease","ADACT","Inclusion Criteria:\n\nPatient group: Diagnosis of Alzheimer's disease made by one of the consulting physicians-a neurologist and\u002For geriatrician (Dubois et al., 2014)-at the early stage, presenting with mild memory impairment of which the patient has been informed\n\n\\- MMSE score of 21 or higher\n\nControl group: individuals without a diagnosis of Alzheimer's disease, but meeting the other criteria listed below\n\n* Enrollment in a social security program\n* Age 60 or older\n* French as a native language\n* Consent to participate\n\nExclusion Criteria:\n\n* Uncorrected visual or hearing impairments\n* Language or motor impairments\n* Delirium or psychosis.\n* Medical treatment affecting vision, language, or motor skills (or participation in a study involving a drug or device that influences cognition).\n* Refusal to participate.\n* Inability to communicate\n* Persons deprived of liberty by a judicial or administrative decision and adults subject to a legal protection measure or unable to express their consent","60 Years",{"count":52,"type":22},80,"INTERVENTIONAL",[55],"NA","In France, over 1.5 million people suffer from mild cognitive impairment, often a precursor to Alzheimer's disease (AD), whose global prevalence could reach 153 million by 2050. With no curative treatment available, maintaining patients' autonomy at home is essential to mitigate the negative effects of institutionalization and reduce economic costs. Non-pharmacological approaches, such as cognitive training, have shown potential in stabilizing cognitive functions. Research suggests that motor networks and procedural memory remain relatively preserved in early AD, and bodily engagement during encoding enhances memory. For patients with motor impairments, motor imagery (MI) activates these networks without actual movement. Additionally, dynamic visual cues, like videos, reduce cognitive load compared to static images. This project aims to combine real action, MI, and dynamic visual supports to optimize memory. By validating 120 videos of daily activities, it will assess the impact of action on recall, evaluate MI's effectiveness for patients with mobility limitations, and confirm the superiority of videos over static images. The results could support the development of digital tools, such as serious games, to enhance patients' autonomy and address aging-related challenges.",[58,26],"Alzheimer s Disease",[60,61,62,63,64,65],"Alzheimer's disease","memory remediation","motor-enriched encoding","imagery","static imagery","dynamic imagery","2026-06-02",{"date":68,"type":34},"2026-06-08",{"date":70,"type":22},"2026-06-20",{"date":72,"type":22},"2028-06",{"name":74,"class":41},"Centre Hospitalier Universitaire de Saint Etienne",3,{"id":77,"slug":78,"hasResults":11,"nctId":79,"briefTitle":80,"officialTitle":80,"acronym":4,"eligibilityCriteria":81,"healthyVolunteers":11,"sex":18,"minAge":19,"maxAge":82,"enrollmentInfo":83,"targetDuration":85,"studyType":23,"phases":4,"briefSummary":86,"conditions":87,"keywords":4,"overallStatus":88,"whyStopped":4,"lastUpdateSubmitDate":89,"lastUpdatePostDateStruct":90,"startDateStruct":92,"completionDateStruct":94,"leadSponsor":96,"locationsCount":42},"100638253","correlation-studies-on-human-body-composition-based-on-bioequivalence-or-pharmacokinetic-trials-100638253","NCT07611929","Correlation Studies on Human Body Composition Based on Bioequivalence or Pharmacokinetic Trials","Inclusion Criteria:\n\n1. Participants who have been successfully enrolled in the bioequivalence trials of Progesterone Sustained-release vaginal gel；\n2. Have signed the informed consent form, have a full understanding of the content, process, and risks of this study, and can communicate well with the researchers.\n\nExclusion Criteria:1:\n\n1）Participants who may not be able to complete the study for other reasons or are deemed by the investigator to be unsuitable for participation in this study.","65 Years",{"count":84,"type":22},3000,"1 Day","The aim of this observational study is to investigate the impact of body composition on the absorption, distribution, and metabolism of drugs. The primary question it seeks to answer is: Does body composition affect the absorption, distribution, and metabolism of drugs? By combining pharmacokinetic parameters and adverse drug reactions, the study will analyze differences in the metabolism of drugs under various body composition conditions.\n\nDuring the Phase I clinical trial, under the guidance of the researchers, subjects will use the non-invasive InBody S10 body composition analyzer to obtain body composition data, including but not limited to inorganic salts, muscle mass, lean body mass, body weight, and body fat percentage.",[26],"RECRUITING","2026-05-21",{"date":91,"type":34},"2026-05-28",{"date":93,"type":34},"2024-10-05",{"date":95,"type":22},"2029-12-31",{"name":97,"class":41},"Second Affiliated Hospital of Wenzhou Medical University",{"id":99,"slug":100,"hasResults":11,"nctId":101,"briefTitle":102,"officialTitle":103,"acronym":4,"eligibilityCriteria":104,"healthyVolunteers":11,"sex":18,"minAge":19,"maxAge":105,"enrollmentInfo":106,"targetDuration":85,"studyType":23,"phases":4,"briefSummary":108,"conditions":109,"keywords":112,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":117,"lastUpdatePostDateStruct":118,"startDateStruct":120,"completionDateStruct":122,"leadSponsor":124,"locationsCount":42},"100634497","the-effect-of-different-acoustic-conditions-on-6-minute-walk-test-performance-and-recovery-100634497","NCT07540455","The Effect of Different Acoustic Conditions on 6-Minute Walk Test Performance and Recovery","An Investigation of the Effect of Different Auditory Conditions on 6-Minute Walk Performance and Recovery in Healthy Young Adults: A Randomised Cross-Over Study","Inclusion Criteria:\n\n* Aged between 18 and 35,\n* Able to walk unaided (without the use of a walking aid),\n* Participants who agree to take part in the study on a voluntary basis and sign the informed consent form\n\nExclusion Criteria:\n\n* A history of myocardial infarction or unstable angina within the last month,\n* Acute illness or pain during the test that would prevent walking,\n* A lower limb injury or surgery within the last 3 months,\n* Resting systolic blood pressure \\>180 mmHg or diastolic blood pressure \\>100 mmHg,\n* Resting heart rate exceeding 120 beats per minute,\n* Those with cardiovascular or pulmonary conditions that may limit exercise,\n* Those with neurological conditions (balance disorders, stroke, epilepsy, etc.),\n* Those with musculoskeletal problems (lower limb fracture, severe arthritis, acute injury, etc.),\n* Those with an acute infection, fever or severe fatigue that could prevent walking during the test,\n* Those with a body mass index of 35 or above (obesity),\n* Those with a history of active vertigo, Meniere's disease or vestibular system disorders,\n* Participants with a diagnosed hearing problem","35 Years",{"count":107,"type":22},40,"Study Design: Randomized Cross-Over Study\n\nObjective:\n\nThis study aims to compare the acute effects of three different auditory conditions (metronome, binaural beats, and silent control) on 6-Minute Walk Test (6MWT) performance, post-exercise recovery physiology, and perceived exertion in healthy young adults.\n\nBackground:\n\nAuditory-motor coupling mechanisms suggest that rhythmic auditory stimuli can lower the excitation threshold of motor neurons, thereby enhancing walking efficiency. Rhythmic stimuli such as metronomes are known to improve walking speed and coordination. Binaural beats are an auditory stimulus type generated by presenting two tones of slightly different frequencies to each ear, triggering cortical neural entrainment. It has been reported that listening to binaural beats at theta frequency following exercise increases parasympathetic activation and accelerates recovery. This study aims to examine these two auditory stimuli in comparison with a control condition in healthy young adults.\n\nParticipants:\n\nHealthy young adults aged 18-35 who can walk independently and have no cardiovascular, pulmonary, neurological, or musculoskeletal conditions. Minimum sample size will be calculated using G\\*Power following a pilot study, with a 20% dropout margin added.\n\nRandomization:\n\nAll participants will be exposed to all three conditions on separate days. The order of application will be determined by computer-based simple randomization (randomizer.org). Six possible sequence combinations will be used to balance order effects. A washout period of at least 24 hours will be applied between sessions.\n\nInterventions:\n\nMetronome Condition: Each participant's natural walking cadence will be measured, and the metronome tempo will be set at 110% of this baseline value.\n\nBinaural Beats Condition: A carrier frequency of 120 Hz will be delivered to the right ear and 100 Hz to the left ear, generating a 20 Hz binaural beat in the Beta frequency band. Participants will listen for 6 minutes at rest immediately before the walking test.\n\nControl Condition: No auditory stimulus will be applied.\n\nThe 6MWT will be conducted in all conditions along a 30-meter flat corridor in accordance with ATS\u002FERS standards.\n\nMeasurement Time Points: Pre-test, immediately post-test, and at the 1st, 3rd, and 5th minutes of the recovery period.\n\nOutcome Measures:\n\nPrimary: Total distance covered during 6MWT (meters), walking cadence (steps\u002Fmin) Secondary: Heart rate, blood pressure, peripheral oxygen saturation (SpO₂), perceived dyspnea, general fatigue, and quadriceps femoris muscle fatigue assessed via the Modified Borg Scale\n\nStatistical Analysis:\n\nOne-Way Repeated Measures ANOVA for walking distance and cadence; Two-Way Repeated Measures ANOVA (condition × time) for physiological parameters; Friedman test for Borg scale data; Bonferroni-corrected post-hoc tests where significant differences are found. Significance level set at p\\\u003C0.05.\n\nStudy Duration: April - June 2026 (3 months)",[110,111,26],"Recovery","Fatigue Recovery",[113,114,115,116],"6 minutes walk test","metronome","binaural","recovery","2026-04-14",{"date":119,"type":34},"2026-04-20",{"date":121,"type":22},"2026-04-15",{"date":123,"type":22},"2026-07-01",{"name":125,"class":41},"Hasan Kalyoncu University",{"id":127,"slug":128,"hasResults":11,"nctId":129,"briefTitle":130,"officialTitle":130,"acronym":4,"eligibilityCriteria":131,"healthyVolunteers":17,"sex":18,"minAge":19,"maxAge":132,"enrollmentInfo":133,"targetDuration":4,"studyType":53,"phases":135,"briefSummary":137,"conditions":138,"keywords":4,"overallStatus":88,"whyStopped":4,"lastUpdateSubmitDate":139,"lastUpdatePostDateStruct":140,"startDateStruct":142,"completionDateStruct":144,"leadSponsor":146,"locationsCount":42},"100633027","phase-1-a-phase-i-study-to-evaluate-the-safety-tolerability-pharmacokinetics-and-the-food-effect-of-hsk55879-tablets-in-healthy-subjects-100633027","NCT07521345","A Phase I Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and the Food Effect of HSK55879 Tablets in Healthy Subjects.","Inclusion Criteria:\n\n1. Able to understand the nature, purpose, and requirements of the study, as well as the potential risks and adverse reactions, and have signed the written informed consent form prior to the start of the study;\n2. Healthy subjects aged 18 to 45 years (inclusive) at screening, male or female;\n3. Body weight ≥50 kg for male subjects and ≥45 kg for female subjects at screening, with a body mass index (BMI) within the range of 19.0-28.0 kg\u002Fm² (inclusive);\n4. Subjects (including their partners) agree to have no pregnancy plan from 14 days before screening until 3 months after the last dose, and agree to use reliable contraceptive measures during this period.\n\nExclusion Criteria:\n\n1. Any history of disease that, in the investigator's judgment, may affect the safety evaluation of the subject or the in vivo disposition of the study drug,\n2. Physical examination, vital signs, laboratory tests，abdominal ultrasound, or chest X-ray findings that are judged by the study physician to be clinically significant abnormalities;\n3. Previous or current gastrointestinal, hepatic, renal, or other diseases known to interfere with drug absorption, distribution, metabolism, or excretion;\n4. abnormal HbA1c at screening;\n5. Abnormal liver function test results\n6. Estimated glomerular filtration rate (eGFR) calculated by the Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) equation \\\u003C90 mL\u002Fmin\u002F1.73 m² at screening;\n7. Routine 12-lead electrocardiogram (ECG) findings that are not consistent with normal cardiac conduction and function.\n8. History of gastrointestinal diseases, with current symptoms of digestive discomfort ;\n9. Current or past history of drug abuse, or a positive urine drug screen at screening;\n10. Positive test for hepatitis B surface antigen (HBsAg), hepatitis C antibody, syphilis antibody, or human immunodeficiency virus (HIV) antibody at screening;\n11. Pregnant or breastfeeding females;\n12. Subjects who, in the investigator's opinion, have poor compliance or any other factor that makes them unsuitable for participation in this study.\n\n    \\-","45 Years",{"count":134,"type":22},46,[136],"PHASE1","This is a single-center, random, double blind, placebo control clinical study to evaluate the safety, tolerability pharmacokinetics and food effect of HSK55879 in healthy subjects",[26],"2026-04-03",{"date":141,"type":34},"2026-04-09",{"date":143,"type":34},"2026-03-20",{"date":145,"type":22},"2026-06-15",{"name":147,"class":148},"Haisco Pharmaceutical Group Co., Ltd.","INDUSTRY",{"id":150,"slug":151,"hasResults":11,"nctId":152,"briefTitle":153,"officialTitle":154,"acronym":4,"eligibilityCriteria":155,"healthyVolunteers":17,"sex":18,"minAge":19,"maxAge":156,"enrollmentInfo":157,"targetDuration":4,"studyType":53,"phases":159,"briefSummary":160,"conditions":161,"keywords":162,"overallStatus":88,"whyStopped":4,"lastUpdateSubmitDate":164,"lastUpdatePostDateStruct":165,"startDateStruct":167,"completionDateStruct":169,"leadSponsor":171,"locationsCount":42},"100626973","phase-1-a-study-to-assess-effect-of-dosing-intervals-on-multiple-dose-pharmacokinetics-of-wd-1603-taken-before-meals-in-healthy-participants-100626973","NCT07442591","A Study to Assess Effect of Dosing Intervals on Multiple-Dose Pharmacokinetics of WD-1603 Taken Before Meals in Healthy Participants","A Clinical Study to Assess the Effect of Different Dosing Intervals on the Multiple-Dose Pharmacokinetics of WD-1603 (25mg Carbidopa\u002F150mg Levodopa) When Administered Before Meals in Healthy Participants","Inclusion Criteria:\n\n* Healthy adult male or female participants aged 18 to 55 years (inclusive) at the time of signing the informed consent form (ICF).\n* Body weight: male ≥ 50 kg, female ≥ 45 kg; body mass index (BMI) between 18 and 27 kg\u002Fm² (inclusive) (BMI = weight \\[kg\\] \u002F height² \\[m²\\]).\n* Medical history inquiry, physical examination, vital signs, laboratory tests (complete blood count, urinalysis, blood biochemistry, serological virology tests, coagulation function), 12-lead ECG, intraocular pressure measurement, abdominal ultrasound, and chest X-ray during the screening period are all within normal ranges or clinically insignificant if outside normal ranges.\n* Participants (including their spouses or partners) have no plans for conception or for donating sperm\u002Feggs from the time of signing the ICF (for females)\u002Ffirst dosing (for males) until 3 months after the last dose, and voluntarily agree to use effective non-pharmacological contraception during the trial period.\n* Fully understand the trial content, procedures, and potential adverse reactions, voluntarily agree to participate, and sign the ICF before any trial-related procedures begin.\n* Able to communicate well with the investigators and capable of understanding and complying with the requirements of this trial.\n\nExclusion Criteria:\n\n* Allergy-prone constitution, history of allergic diseases, or known severe allergic reaction or allergy history to levodopa\u002Fcarbidopa or related medications.\n* Drug use within 3 months prior to screening, history of drug abuse, or positive urine drug abuse screening (morphine, methamphetamine, ketamine, methylenedioxymethamphetamine, tetrahydrocannabinol acid, cocaine).\n* History of glaucoma, cancer, diabetes mellitus, bronchial asthma, or any clinically significant cardiovascular, respiratory, metabolic, renal, hepatic, gastrointestinal, hematological, dermatological, endocrine, neuropsychiatric diseases, or other significant conditions.\n* Dysphagia or any condition that may affect drug absorption (e.g., gastrectomy, cholecystectomy, gastric bypass, duodenotomy, colectomy), or gastrointestinal diseases causing clinically significant symptoms such as nausea, vomiting, diarrhea, or malabsorption syndrome.\n* History of orthostatic hypotension.\n* Any relevant medical history, surgical history, or trauma within 3 months prior to the first dose that may affect trial safety or drug pharmacokinetics, or planned surgery during the trial period.\n* Use of prescription drugs, over-the-counter medications, health products, Chinese herbal medicines, or dietary supplements within 4 weeks prior to the first dose, especially monoamine oxidase inhibitors (e.g., phenelzine, rasagiline, selegiline, brofaromine, toloxatone, isocarboxazid, etc.).\n* Participation in any clinical trial and receipt of investigational drugs within 3 months prior to the first dose.\n* Blood donation (including component blood) or significant blood loss (≥400 mL), blood transfusion, or use of blood products within 3 months prior to the first dose.\n* Difficulty with venous access, unsuitability or unwillingness to use intravenous catheters, or history of needle\u002Fblood phobia.\n* Heavy smokers or average daily cigarette consumption of more than 10 cigarettes within 3 months prior to screening.\n* Alcohol consumption exceeding 21 standard units per week within 3 months prior to screening (1 standard unit contains 14g of alcohol, e.g., 360 mL of beer, 45 mL of 40% spirits, or 150 mL of wine), positive alcohol breath test, or unwillingness to abstain from alcohol from 48 hours before the first dose of each period until the completion of blood sampling for that period.\n* Estimated glomerular filtration rate (eGFR) \\\u003C 90 mL\u002Fmin·1.73m² during the screening period.\n* During screening: systolic blood pressure \\\u003C 90 mmHg or ≥ 140 mmHg, diastolic blood pressure \\\u003C 60 mmHg or ≥ 90 mmHg, pulse rate \\> 100 beats\u002Fmin or \\\u003C 50 beats\u002Fmin.\n* History of prolonged QT interval or other clinically significant cardiac diseases, or QTcF ≥ 450 ms on ECG during screening.\n* Symptoms of acute infection (e.g., influenza) or acute gastroenteritis within 2 weeks prior to screening, or history of vomiting or diarrhea within 1 week prior to screening.\n* Positive for hepatitis B surface antigen (HBsAg), hepatitis C virus antibody (HCV-Ab), human immunodeficiency virus antibody (HIV-Ab), or Treponema pallidum antibody.\n* Currently pregnant (including positive pregnancy test) or lactating female.\n* Poor compliance as judged by the investigator, or other factors deemed unsuitable for participation in this trial.","55 Years",{"count":158,"type":22},12,[136],"WD-1603 contains two different drugs called levodopa and carbidopa in one tablet. The goal of this clinical trial is to see if taking the study drug WD-1603 at different time intervals affects how the drug acts in healthy volunteers. We also want to learn about the safety of WD-1603.\n\nThe main question we want to answer is:\n\n* How does the body process WD-1603 when it is taken by different time intervals? What will participants do?\n* Participants will take one tablet of WD-1603 twice a day on three separate days.\n* On each dosing day, the two doses will be spaced different hours apart.\n* Between each dosing day, there will be a rest period of up to 7 days.",[26],[163],"multiple-dose, open-label, pharmacokinetic","2026-04-02",{"date":166,"type":34},"2026-04-08",{"date":168,"type":34},"2026-03-24",{"date":170,"type":22},"2026-12",{"name":172,"class":148},"Shanghai WD Pharmaceutical Co., Ltd.",{"id":174,"slug":175,"hasResults":11,"nctId":176,"briefTitle":177,"officialTitle":178,"acronym":4,"eligibilityCriteria":179,"healthyVolunteers":17,"sex":18,"minAge":180,"maxAge":181,"enrollmentInfo":182,"targetDuration":4,"studyType":53,"phases":184,"briefSummary":185,"conditions":186,"keywords":4,"overallStatus":88,"whyStopped":4,"lastUpdateSubmitDate":187,"lastUpdatePostDateStruct":188,"startDateStruct":190,"completionDateStruct":191,"leadSponsor":193,"locationsCount":42},"100626278","phase-1-safety-tolerability-pharmacokinetic-and-pharmacodynamic-of-iy-828026-in-healthy-volunteers-100626278","NCT07433556","Safety, Tolerability, Pharmacokinetic and Pharmacodynamic of IY-828026 in Healthy Volunteers","A Randomized, Double-blinded, Partial-open, Placebo\u002FActive-controlled, Single\u002FMultiple Dosing, Dose Escalation Phase 1 Clinical Trial to Evaluate the Safety, Tolerability, Pharmacokinetic, and Pharmacodynamic Characteristics of IY-828026 in Healthy Adult Volunteers","Inclusion Criteria:\n\n* Healthy adult volunteers aged ≥ 19 and ≤ 50 years at screening\n* Body weight ≥ 50.0 kg to ≤ 90.0 kg and body mass index (BMI) of ≥ 18.5 kg\u002Fm2 to ≤ 29.9 kg\u002Fm2 at screening\n* Volunteers who were fully informed of and completely understood this study, voluntarily agreed to participate, and provided written consent to comply with the precautions\n\nExclusion Criteria:\n\n* Current or history of clinically significant disease of hepatobiliary (severe hepatic impairment, viral hepatitis, etc.), renal (severe renal impairment, etc.), nervous, immune, respiratory, gastrointestinal, endocrine, hemato-oncologic, cardiovascular (heart failure, torsades de pointes, etc.), urinary, or psychiatric (mood disorder, obsessive compulsory disorder, etc.) system or sexual dysfunctions\n* H. pylori eradication treatment within 6 months or positive result for H. pylori at screening\n* Hypersensitivity or history of clinically significant hypersensitivity to PPIs, P-CABs, and other drugs (aspirin, antibiotics, etc.)\n* A positive result in serology (hepatitis B tests, hepatitis C tests, human immunodeficiency virus \\[HIV\\] tests, or syphilis tests)\n* History of drug abuse or positive results for drug abuse in the urine drug screen","19 Years","50 Years",{"count":183,"type":22},86,[136],"A randomized, double-blinded, partial-open, placebo\u002Factive-controlled, single\u002Fmultiple dosing, dose escalation phase 1 clinical trial to evaluate the safety, tolerability, pharmacokinetic, and pharmacodynamic characteristics of IY-828026 in healthy adult volunteers",[26],"2026-03-23",{"date":189,"type":34},"2026-03-27",{"date":187,"type":34},{"date":192,"type":22},"2027-06",{"name":194,"class":148},"Il-Yang Pharm. Co., Ltd.",{"id":196,"slug":197,"hasResults":11,"nctId":198,"briefTitle":199,"officialTitle":200,"acronym":4,"eligibilityCriteria":201,"healthyVolunteers":17,"sex":18,"minAge":19,"maxAge":132,"enrollmentInfo":202,"targetDuration":4,"studyType":53,"phases":204,"briefSummary":205,"conditions":206,"keywords":4,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":143,"lastUpdatePostDateStruct":207,"startDateStruct":208,"completionDateStruct":210,"leadSponsor":212,"locationsCount":4},"100630994","effects-of-vibrational-therapy-on-pelvic-floor-muscle-strength-and-tone-in-healthy-women-100630994","NCT07494903","Effects of Vibrational Therapy on Pelvic Floor Muscle Strength and Tone in Healthy Women","Effects of Mechanical Vibration Applied to the Pelvic Floor Musculature: A Quasi-Experimental Study","Inclusion Criteria:\n\n* Throughout the intervention (ongoing during each session) and Post-intervention (after 8 weeks of treatment).\n\nExclusion Criteria:\n\n* 1\\. Urogenital Infections: Presence of any active urogenital infections. 2. Abdominal or Pelvic Surgery: History of abdominal or pelvic surgery. 3. Active Menstruation: Women who are menstruating at the time of the study. 4. Breastfeeding: Participants who are actively breastfeeding. 5. Mictrurition Symptoms: Presence of any urinary symptoms. 6. Pain: Pain upon palpation of the central fibrous nucleus of the perineum. 7. Sensory Alterations: Presence of altered sensitivity such as hypoalgesia, hyperalgesia, or allodynia.\n\n  8\\. Spinal Lesions: History of spinal cord injuries. 9. Neurological Conditions: Any neurological disorders. 10. Pelvic Organ Prolapse: Diagnosed prolapse of pelvic organs. 11. Obesity: Body Mass Index (BMI) ≥ 30 kg\u002Fm². 12. Active Oncology Treatment: Any current or recent cancer treatments. 13. Pregnancy: Women who are pregnant. 14. Pelvic Floor Pathologies: Diagnosed pelvic floor dysfunctions. 15. Ongoing Pelvic Floor Treatment: Participants currently receiving active pelvic floor treatments.\n\n  16\\. Dermatological Pathologies: Any active vulvar dermatological conditions.",{"count":203,"type":22},60,[55],"This quasi-experimental study aims to evaluate the effects of mechanical vibration applied to the pelvic floor musculature in healthy women aged 18-45. The intervention involves vibrational therapy targeting the central fibrous nucleus of the perineum, with the goal of assessing changes in muscle tone, strength, and biomechanical properties. The study will also examine the tolerance to this technique, with data collected at baseline and after 8 weeks of treatment.",[26],{"date":189,"type":34},{"date":209,"type":22},"2026-06-01",{"date":211,"type":22},"2026-12-01",{"name":213,"class":41},"Universidad Europea de Madrid",{"id":215,"slug":216,"hasResults":11,"nctId":217,"briefTitle":218,"officialTitle":219,"acronym":220,"eligibilityCriteria":221,"healthyVolunteers":17,"sex":18,"minAge":19,"maxAge":222,"enrollmentInfo":223,"targetDuration":4,"studyType":53,"phases":224,"briefSummary":225,"conditions":226,"keywords":4,"overallStatus":88,"whyStopped":4,"lastUpdateSubmitDate":227,"lastUpdatePostDateStruct":228,"startDateStruct":229,"completionDateStruct":231,"leadSponsor":233,"locationsCount":42},"100630941","phase-1-acute-analgesic-effects-of-mdma-on-experimentally-induced-acute-pain-hyperalgesia-and-allodynia-in-healthy-participants-100630941","NCT07494214","Acute Analgesic Effects of MDMA on Experimentally Induced Acute Pain, Hyperalgesia and Allodynia in Healthy Participants","Acute Analgesic Effects of 3,4-methylenedioxymethamphetamine (MDMA) on Experimentally Induced Acute Nociceptive Pain, Hyperalgesia and Allodynia in Healthy Participants (MDPS-study)","MDPS","Inclusion Criteria:\n\n1. Age between 18 and 75 years old\n2. Sufficient understanding of the German language\n3. Understanding of procedures and risks associated with the study\n4. Willing to adhere to the protocol and signing of the consent form\n5. Willing to refrain from the consumption of illicit psychoactive substances during the study\n6. Willing not to operate heavy machinery for 48 hours after the study session.\n7. Willing to use effective birth control throughout study participation\n8. Body mass index between 18-34.9 kg\u002Fm2\n\nExclusion Criteria:\n\n1. Relevant chronic or acute medical condition\n2. Any implanted medical devices (e.g., pacemakers, neurostimulators, or metal prostheses)\n3. Current or previous major psychiatric disorder (e.g. bipolar disorder, schizophrenia), current depression or anxiety disorder.\n4. Psychotic disorder or bipolar disorder in first-degree relatives\n5. Hypertension (SBP\\>140\u002F90 mmHg) or hypotension (SBP\\\u003C85 mmHg)\n6. Lifetime use of MDMA on more than 20 occasions or any use within the previous two months\n7. Pregnancy or current breastfeeding\n8. Participation in another clinical trial (currently or within the last 30 days)\n9. Use of medication that may interfere with the effects of the study medication\n10. Tobacco smoking (\\>10 cigarettes\u002Fday)\n11. Consumption of alcoholic beverages (\\>15 drinks\u002Fweek)","75 Years",{"count":21,"type":22},[136],"This study investigates whether MDMA may have a pain-reducing effect. The effect of MDMA is compared with a placebo (a substance with no active effect).\n\nIn the study, moderate pain will be artificially created in healthy participants using repeated small electrical pulses applied under the skin. At the same time, participants will take MDMA or a placebo by mouth. This allows researchers to compare how MDMA affects the artificially created pain. A total of 20 healthy volunteers will take part in this study.",[26],"2026-03-19",{"date":189,"type":34},{"date":230,"type":34},"2026-03-09",{"date":232,"type":22},"2027-04-09",{"name":234,"class":41},"University Hospital, Basel, Switzerland",{"id":236,"slug":237,"hasResults":11,"nctId":238,"briefTitle":239,"officialTitle":239,"acronym":240,"eligibilityCriteria":241,"healthyVolunteers":17,"sex":18,"minAge":19,"maxAge":242,"enrollmentInfo":243,"targetDuration":4,"studyType":53,"phases":245,"briefSummary":246,"conditions":247,"keywords":4,"overallStatus":88,"whyStopped":4,"lastUpdateSubmitDate":230,"lastUpdatePostDateStruct":251,"startDateStruct":253,"completionDateStruct":255,"leadSponsor":257,"locationsCount":42},"100607048","metabolic-effects-of-short-chain-fatty-acids-in-healthy-individuals-100607048","NCT07183488","Metabolic Effects of Short-Chain Fatty Acids in Healthy Individuals","SCFA","Inclusion Criteria:\n\n* Male or female.\n* Age between 18-40 years old\n* BMI between 18.5-29\n\nExclusion Criteria:\n\n* Diabetes\n* Kidney- or liver disease\n* Pregnant, lactating or planning to become pregnant within the study period\n* Supplementation with SCFAs\n* Supplementation with B12 vitamin\n* Special dietary habits (e.g. vegan\u002Fketogenic diet)\n* Ongoing cancer treatment\n* Metabolic or absorptive disorders, gastric bypass operation, or use of medication affecting metabolism or food absorption\n* Crohn's disease, ulcerative colitis or short bowel syndrome\n* Inability, physically or mentally, to comply with the procedure required by the study protocol as evaluated by the primary investigator, study manager or clinical responsible","40 Years",{"count":244,"type":22},10,[55],"The primary objective of this study is to investigate the acute physiological and metabolic effects of ingesting the short-chain fatty acids (SCFA)s propionate (three carbon atoms long; C3:0) and butyrate (C4:0) in healthy men and women. This aim will be addressed through a block-randomized cross-over study including two visits with acute intake of propionate and butyrate, respectively.\n\nThe hypothesis is that plasma ketone body levels will increase during the first three hours after intake of butyrate, but not propionate, in healthy individuals in the overnight fasted state.",[26,248,249,250],"Other: Short-Chain Fatty Acid (SCFA)","Other: Butyrate (C4)","Other: Propionate (C3)",{"date":252,"type":34},"2026-03-10",{"date":254,"type":34},"2025-09-10",{"date":256,"type":22},"2030-09-01",{"name":258,"class":41},"University of Copenhagen",{"id":260,"slug":261,"hasResults":11,"nctId":262,"briefTitle":263,"officialTitle":264,"acronym":4,"eligibilityCriteria":265,"healthyVolunteers":17,"sex":266,"minAge":50,"maxAge":267,"enrollmentInfo":268,"targetDuration":4,"studyType":53,"phases":270,"briefSummary":271,"conditions":272,"keywords":277,"overallStatus":88,"whyStopped":4,"lastUpdateSubmitDate":282,"lastUpdatePostDateStruct":283,"startDateStruct":285,"completionDateStruct":287,"leadSponsor":289,"locationsCount":42},"100626282","video-game-intervention-in-older-adults-100626282","NCT07433608","Video Game Intervention In Older Adults","The Effects Of A Video-Based Game Intervention On Cognitive, Physical And Psychosocial Outcomes In Older Adults","Inclusion Criteria:\n\nAge 60 years or older A score of 24 or higher on the Mini Mental State Examination (MMSE) Ability to understand and follow verbal instructions Willingness to participate voluntarily\n\nExclusion Criteria:\n\nPresence of a neurological, orthopedic, or psychiatric diagnosis Medical contraindications to exercise Diagnosis of dementia Acute orthopedic injury Visual or hearing impairment that would interfere with participation Inability to attend sessions regularly","FEMALE","69 Years",{"count":269,"type":22},32,[55],"The purpose of this clinical trial is to investigate the effects of a rehabilitative game-based intervention on self-efficacy, balance, and visual-motor integration in individuals aged 60 years and older.\n\nThe primary research questions are:\n\nDoes the rehabilitative game-based intervention improve balance and visual-motor integration? Does the rehabilitative game-based intervention improve self-efficacy levels?\n\nResearchers will compare a rehabilitative game intervention group with a control group. Participants will complete baseline and post-intervention assessments. Individuals in the intervention group will participate in rehabilitative game sessions twice per week for 6 weeks, while the control group will not receive any intervention.",[26,273,274,275,276],"Aging","Balance","Self Efficacy","Visual Motor Integration",[278,279,280,274,281],"Virtual Reality","Visual-Motor Integration","Older Adults","Self-Efficacy","2026-03-03",{"date":284,"type":34},"2026-03-06",{"date":286,"type":34},"2026-02-17",{"date":288,"type":22},"2026-04-07",{"name":290,"class":41},"Biruni University",{"id":292,"slug":293,"hasResults":11,"nctId":294,"briefTitle":295,"officialTitle":296,"acronym":297,"eligibilityCriteria":298,"healthyVolunteers":17,"sex":18,"minAge":181,"maxAge":4,"enrollmentInfo":299,"targetDuration":4,"studyType":53,"phases":300,"briefSummary":301,"conditions":302,"keywords":4,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":305,"lastUpdatePostDateStruct":306,"startDateStruct":308,"completionDateStruct":310,"leadSponsor":312,"locationsCount":4},"100626242","validation-of-virtual-reality-tests-for-the-assessment-of-patients-with-age-related-macular-degeneration-as-clinical-endpoints-100626242","NCT07433088","Validation of Virtual Reality Tests for the Assessment of Patients With Age-related Macular Degeneration as Clinical Endpoints","Validation of Virtual Reality Tests for the Assessment of Patients With Age-related Macular Degeneration","VIRETTA","Inclusion Criteria:\n\n* Age ≥ 50 years\n* Sufficient knowledge of the French language\n* Ability to give personal, express, free, and informed consent\n* Ability to comply with the requirements of the protocol\n* Person covered by Social Security\n* Clarity of the ocular environment, adequate pupil dilation to allow the collection of good quality images, as determined by the investigator\n\nAdditional inclusion criteria for group 1, healthy subjects:\n\n* No detectable visual pathologies\n* Best monocular visual acuity ≥ 8\u002F10\n\nAdditional inclusion criteria for group 2, subjects with LMA, early AMD, or intermediate AMD without atrophy:\n\n* Diagnosis of AMD, early AMD, or intermediate AMD\n* Absence of geographic atrophy\n* Presence of drusen (diameter \\> 63 µm) with or without pigmentary changes\n\nAdditional inclusion criteria for group 3, subjects with dry AMD with perifoveal atrophy:\n\n* Diagnosis of atrophic AMD\n* Presence of drusen (diameter \\> 125 µm)\n* Location of geographic atrophy as determined by the investigator: extrafoveal, juxtafoveal\n* Preservation of central vision confirmed by the investigator based on a comprehensive and integrated interpretation of SD-OCT, FAF, retinography, and best corrected visual acuity examinations.\n\nAdditional inclusion criteria for group 4, Subject with dry AMD with foveal atrophy:\n\n* Diagnosis of atrophic AMD\n* Presence of drusen (diameter \\> 125 µm)\n* Investigator's localization of geographic atrophy: retrofoveal\n* Central vision impairment confirmed by the investigator based on a comprehensive and integrated interpretation of SD-OCT, FAF, retinography, and best corrected visual acuity examinations.\n\nExclusion Criteria:\n\n* Pregnant women, women in labor, or breastfeeding women\n* Subjects undergoing drug treatments that may cause motor, visual, vestibular, or cognitive disorders (PSA, neuroleptics, etc.) or that could interfere with the study examinations\n* Any concomitant intraocular condition in the eye being studied (e.g., glaucoma or cataract)\n* Any retinal pathology that could cause retinal atrophy other than AMD (eliminate dystrophy, chronic CRSC, pachyatrophy, resorption of vitelliform material with atrophy, high myopia, etc.)\n* Known systemic disease that, in the investigator's opinion, would prevent active participation in the study\n* Participation in any other therapeutic study evaluating a drug.\n* Subjects with cognitive impairment, illiterate subjects, and subjects who do not speak the national language.\n* Persons subject to enhanced protection or legal safeguards (guardianship, trusteeship).",{"count":203,"type":22},[55],"Age-related macular degeneration (AMD) is the leading cause of irreversible blindness in industrialized countries and affects tens of millions of people worldwide, with a rapidly increasing prevalence. It causes irreversible central vision loss and significant difficulties in daily activities, impairing patients' quality of life and independence. Conventional clinical assessments, which focus on visual acuity and retinal imaging, do not fully reflect the functional impact of the disease.\n\nVirtual reality (VR) makes it possible to create immersive, controlled environments to accurately measure functional vision and simulate real-life situations. The study proposes to develop a standardized and reproducible functional test in virtual reality that can complement conventional examinations and support clinical and industrial research.",[303,304,26],"Dry AMD","Geographic Atrophy","2026-02-18",{"date":307,"type":34},"2026-02-25",{"date":309,"type":22},"2026-04",{"date":311,"type":22},"2027-04",{"name":313,"class":148},"Streetlab",{"id":315,"slug":316,"hasResults":11,"nctId":317,"briefTitle":318,"officialTitle":319,"acronym":4,"eligibilityCriteria":320,"healthyVolunteers":17,"sex":18,"minAge":321,"maxAge":322,"enrollmentInfo":323,"targetDuration":4,"studyType":53,"phases":325,"briefSummary":326,"conditions":327,"keywords":329,"overallStatus":88,"whyStopped":4,"lastUpdateSubmitDate":331,"lastUpdatePostDateStruct":332,"startDateStruct":334,"completionDateStruct":336,"leadSponsor":338,"locationsCount":42},"100623566","insulin-mediated-glucose-uptake-and-organ-perfusion-assessed-by-total-body-pet-during-gip-and-glp-1-infusion-100623566","NCT07398300","Insulin-Mediated Glucose Uptake and Organ Perfusion Assessed by Total-Body PET During GIP and GLP-1 Infusion","Dynamic Whole-Body FDG and H₂¹⁵O PET-CT to Assess Insulin-Mediated Glucose Uptake and Organ Perfusion During GIP and GLP-1 Infusion in Healthy Individuals and Patients With Type 2 Diabetes","Sub-study 1 (Healthy individuals):\n\n* Age 23-50 years\n* BMI 20.0-26.9 kg\u002Fm²\n* HbA1c \\\u003C 42 mmol\u002Fmol\n* Able to provide informed consent\n\nSub-study 2 - Participants with Type 2 Diabetes:\n\n* Age 23-60 years\n* Diagnosed with type 2 diabetes for ≥3 months\n* HbA1c \\> 53 mmol\u002Fmol\n* Treatment with metformin only\n* Able to provide informed consent\n\nSub-study 2 - Healthy control participants:\n\n* Age 23-64 years\n* HbA1c \\\u003C 42 mmol\u002Fmol\n* Able to provide informed consent\n\nExclusion Criteria (applies to all participants unless otherwise specified):\n\n* Anaemia (haemoglobin below normal range)\n* ALT \\> 2× upper normal limit or any known hepatobiliary or gastrointestinal disorder\n* Kidney disease (creatinine above normal range)\n* Previous gastric or intestinal resection (except appendectomy or cholecystectomy) or major abdominal surgery (including bariatric surgery)\n* For Sub-study 1: Type 1 or type 2 diabetes or HbA1c ≥ 42 mmol\u002Fmol\n* Use of glucose-lowering medications other than metformin (Sub-study 2 only)\n* Chronic obstructive pulmonary disease (Sub-study 2 only)\n* Regular tobacco smoking or use of nicotine-containing products\n* Claustrophobia\n* Pregnancy, breastfeeding, or intention to become pregnant during the study period\n* Initiation of special diets, major lifestyle changes, or weight loss \\> 5% within 3 months prior to or during the study\n* Any medication or physical\u002Fpsychological condition that may interfere with participation (per investigator judgement)\n* Inability to speak or read Danish","23 Years","64 Years",{"count":324,"type":22},36,[55],"This study investigates how the naturally occurring gut hormones GIP and GLP-1 influence whole-body glucose uptake and organ perfusion in humans. Using a state-of-the-art total-body PET-CT scanner, the study measures dynamic uptake of the glucose analogue 18F-FDG and blood flow using H₂¹⁵O across multiple organs during controlled elevations of plasma glucose and endogenous insulin secretion.\n\nThe project consists of two sub-studies. Sub-study 1 includes healthy individuals who undergo three experimental visits with infusions of GIP, GLP-1, or saline (placebo) during a hyperglycemic clamp followed by FDG PET-CT scanning.\n\nSub-study 2 includes healthy individuals and participants with type 2 diabetes who undergo two experimental visits with saline followed by either GIP or GLP-1 during a hyperglycemic clamp, combined with repeated H₂¹⁵O PET-CT measurements of perfusion.\n\nThe primary aims are to quantify insulin-mediated skeletal muscle glucose uptake (sub-study 1) and skeletal muscle perfusion (sub-study 2). Secondary aims include assessment of glucose uptake and perfusion across adipose tissue, liver, and additional organs. The results will provide novel physiological insight into postprandial glucose metabolism and serve as reference data for future whole-body PET research.",[328,26],"Type 2 Diabetes",[330],"IncretinPET","2026-02-04",{"date":333,"type":34},"2026-02-09",{"date":335,"type":22},"2026-03-12",{"date":337,"type":22},"2027-05",{"name":339,"class":41},"Rigshospitalet, Denmark",{"id":341,"slug":342,"hasResults":11,"nctId":343,"briefTitle":344,"officialTitle":344,"acronym":345,"eligibilityCriteria":346,"healthyVolunteers":17,"sex":18,"minAge":4,"maxAge":4,"enrollmentInfo":347,"targetDuration":4,"studyType":53,"phases":348,"briefSummary":349,"conditions":350,"keywords":351,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":357,"lastUpdatePostDateStruct":358,"startDateStruct":360,"completionDateStruct":362,"leadSponsor":363,"locationsCount":4},"100622964","effectiveness-of-artificial-intelligence-integrated-mixed-reality-based-high-alert-medications-management-simulation-program-100622964","NCT07390461","Effectiveness of Artificial Intelligence Integrated Mixed Reality-based High-Alert Medications Management Simulation Program","AIMR-HAM","Inclusion Criteria:\n\n* Nurses with at least one to six years of clinical experience.\n\n  * Those who understand the purpose and procedures of this study and have given written consent to participate.\n\n    * Those who have no physical or cognitive limitations in using mixed reality devices.\n\n      ④ Those who are able to communicate in Korean and understand and respond to questions.\n\nExclusion Criteria:\n\n* Those who do not wish to participate in the study. ② Those who have participated in education related to high-alert medications within the past six months.\n\n  * Those who are unable or have difficulty participating in the mixed reality education program due to visual, hearing, or neurological impairments, or adverse effects such as dizziness or motion sickness.\n\n    * Those who voluntarily withdraw from the study midway through.",{"count":203,"type":22},[55],"The goal of this clinical trial is to learn if a Artificial Intelligence integrated Mixed Reality-based High-Alert Medications Management Simulation Program (AIMR-HAM) helps hospital nurses manage high-alert medicines (HAMs) more safely. MR mixes real and virtual elements to let nurses practice in realistic scenarios.\n\nThe main questions are:\n\nDoes the AIMR-HAM improve nurses' medication safety skills? Does the AIMR-HAM lower medication errors and improve clinical performance?\n\nResearchers will compare two groups to answer these questions:\n\nIntervention group: AIMR-HAM Control group: standard education only\n\nWho can take part:\n\nNurses who work at large hospitals and have 1 to 6 years of clinical experience.\n\nAbout 60 nurses will join the study.\n\nWhat participants will do:\n\nAttend the assigned training (AIMR-HAM or standard education only). Complete short tests and surveys before and after training to measure skills, communication, and clinical reasoning.\n\nReport any medication errors that occur during the study. Why this matters: The study will show whether AIMR-HAM training can improve how nurses handle HAMs and make patient care safer.",[26],[352,353,354,355,356],"High-alert medications","nurse","mixed reality","artificial intelligence","medication safety","2026-01-28",{"date":359,"type":34},"2026-02-05",{"date":361,"type":22},"2026-03-04",{"date":284,"type":22},{"name":364,"class":41},"Chonnam National University Hospital",{"id":366,"slug":367,"hasResults":11,"nctId":368,"briefTitle":369,"officialTitle":370,"acronym":4,"eligibilityCriteria":371,"healthyVolunteers":17,"sex":18,"minAge":19,"maxAge":156,"enrollmentInfo":372,"targetDuration":4,"studyType":53,"phases":373,"briefSummary":374,"conditions":375,"keywords":4,"overallStatus":88,"whyStopped":4,"lastUpdateSubmitDate":377,"lastUpdatePostDateStruct":378,"startDateStruct":380,"completionDateStruct":382,"leadSponsor":384,"locationsCount":42},"100610193","phase-1-evaluate-the-pharmacokinetics-pharmacodynamics-safety-and-tolerability-of-bgm1812-injection-following-single-and-multiple-subcutaneous-administration-in-normal-to-overweight-or-obese-but-otherwise-healthy-men-and-women-100610193","NCT07224399","Evaluate the Pharmacokinetics, Pharmacodynamics, Safety and Tolerability of BGM1812 Injection Following Single and Multiple Subcutaneous Administration in Normal to Overweight or Obese But Otherwise Healthy Men and Women","A Phase 1, Double-Blind, Placebo-Controlled, Dose-Escalation Study to Evaluate the Pharmacokinetics, Pharmacodynamics, Safety and Tolerability of BGM1812 Injection Following Single and Multiple Subcutaneous Administration in Normal to Overweight or Obese But Otherwise Healthy Men and Women","Inclusion Criteria:\n\n* Capable of understanding the written informed consent document; willingly provides valid, signed written informed consent; willing and able to comply with the schedule, requirements and restrictions of the study.\n* Body mass index (BMI) meeting one of the following requirements:\n\n  1. Between ≥ 30.0 kg\u002Fm2 and ≤ 40.0 kg\u002Fm2 (obese) (for Cohort 3-6); OR\n  2. Between ≥ 27.0 kg\u002Fm2 and \\\u003C 30.0 kg\u002Fm2 (overweight) with at least 1 of the following: One or more symptoms of prediabetes (impaired fasting plasma glucose and\u002For abnormal glucose tolerance), grade 1 hypertension, simple fatty liver or dyslipidemia (For Cohort 3- 6); OR\n  3. Between ≥ 23.0 kg\u002Fm2 and \\\u003C 27.0 kg\u002Fm2 healthy subjects (for Cohort 1 and Cohort 2)\n* Have a stable body weight (\\\u003C5% self-reported change during the previous 12 weeks) before screening\n\nExclusion Criteria:\n\n* Have allergic predisposition (allergic to 3 or more foods or drugs), or are allergic to amylin agonist-based therapeutic agents or suffer from severe allergic diseases (asthma, urticaria, eczematous dermatitis).\n* Known type I\u002FII diabetes.\n* Has underwent gastric bariatric surgery in the past, or has had liposuction or fat removal within 1 year before screening, or plan to have bariatric surgery, liposuction or abdominal fat removal during the study period or other surgery that would obviously affect the body weight.\n* History of acute or chronic pancreatitis or pancreatic injury.\n* Has any other conditions or disorders deemed unsuitable for including in the study, in the opinion of the Investigator.",{"count":203,"type":22},[136],"This is a Phase 1, single-center, double-blind, placebo-controlled, dose-escalation study. The study will evaluate the pharmacokinetics (PK), pharmacodynamic (PD), preliminary efficacy, safety and tolerability of BGM1812 following single and multiple SC administrations in normal to overweight or obese but otherwise healthy subjects.",[26,376],"Overweight or Obesity","2025-11-05",{"date":379,"type":34},"2025-11-06",{"date":381,"type":34},"2025-10-09",{"date":383,"type":22},"2026-05-15",{"name":385,"class":148},"BrightGene Bio-Medical Technology Co., Ltd.",{"id":387,"slug":388,"hasResults":11,"nctId":389,"briefTitle":390,"officialTitle":391,"acronym":392,"eligibilityCriteria":393,"healthyVolunteers":17,"sex":266,"minAge":19,"maxAge":105,"enrollmentInfo":394,"targetDuration":4,"studyType":53,"phases":396,"briefSummary":397,"conditions":398,"keywords":399,"overallStatus":88,"whyStopped":4,"lastUpdateSubmitDate":405,"lastUpdatePostDateStruct":406,"startDateStruct":408,"completionDateStruct":410,"leadSponsor":412,"locationsCount":42},"100598912","marmet-and-oxytocin-massage-for-breast-milk-increase-100598912","NCT07077655","Marmet and Oxytocin Massage for Breast Milk Increase","The Effectiveness of the Marmet Technique and Oxytocin Massage on Breast Milk Quantity in Mothers Who Have Undergone Cesarean Section","RCT","Inclusion Criteria:\n\n* Aged between 18-35 years\n* Literate\n* Fluent in Turkish\n* Volunteering to participate in the study\n* Primiparous (first-time mothers)\n* Within the first 2 hours postpartum (mothers performing their first breastfeeding under researcher supervision)\n* Have a single baby with an appropriate birth weight for gestational age (\\>2500 gr)\n* Have their baby with them\n* Received spinal anesthesia\n* Neither the mother nor the baby has any acute or chronic illness\n* Exclusively breastfeeding their baby\n* Had a term (37 weeks gestation or more) and cesarean delivery\n* Experienced no complications after the cesarean section\n* No issues preventing breastfeeding\n* Willing to breastfeed\n\nExclusion Criteria:\n\n* Are under 18 or over 35 years old\n* Are multiparous (have given birth before)\n* Are encountered more than 2 hours postpartum\n* Received general anesthesia\n* Have any acute or chronic illness themselves or their baby\n* Have conditions requiring mother and baby to be separated\n* Report experiencing severe pain\n* Formula-feed their baby or consume any milk-increasing medication or tea\n* Gave birth before 37 weeks gestation or had a vaginal delivery\n* Have an anatomical breast issue (absence of nipple, inverted nipple)\n* Have swelling, ecchymosis, or wounds on their back (for the oxytocin massage group)\n* Have a baby with a congenital anomaly\n* Have an issue preventing breastfeeding\n* Have a psychological issue\n* Are unwilling to breastfeed",{"count":395,"type":22},123,[55],"This study is designed as a randomized controlled single-blind experimental study to examine the effectiveness of the oxytocin massage and Marmet technique applied to mothers who have undergone cesarean section on breast milk quantity and maternal state anxiety levels. The hypotheses of the study are as follows:\n\nH0.1. There is no difference in the amount of breast milk among mothers in the Marmet technique, oxytocin massage, and control (placebo) groups.\n\nH1.1. There is a difference in the amount of breast milk among mothers in the Marmet technique, oxytocin massage, and control (placebo) groups.\n\nH0.2. There is no difference in the state anxiety scale scores among mothers in the Marmet technique, oxytocin massage, and control (placebo) groups.\n\nH1.2. There is a difference in the state anxiety scale scores among mothers in the Marmet technique, oxytocin massage, and control (placebo) groups.\n\nParticipants:\n\nMarmet technique, oxytocin massage, and control (placebo) groups will be informed about the study and asked to provide their consent. Participants will complete the descriptive questionnaire. Colostrum status will be checked and marked as \"present\" or \"absent\" on the \"Breast Milk, Vital Signs, and Pain Level Form.\" Under researcher supervision, the mother will breastfeed her baby. Afterward, the State Anxiety Inventory will be administered.\n\nTwo hours later, mothers will express milk using a hospital-grade pump, with 15 minutes on each breast (total 30 minutes). Milk volume, vital signs, pain levels, and milk flow rate will be recorded on the relevant form. Following this, mothers in the Marmet group will receive 10 minutes of the Marmet technique, mothers in the oxytocin group will receive 5 minutes of oxytocin massage, and mothers in the control group will receive 5 minutes of light touch on their wrists and shoulders. Immediately after, milk expression will again be performed with 15 minutes per breast (30 minutes total). The State Anxiety Inventory will be re-administered, and milk amount, vital signs, pain levels, and flow rate will be recorded again.\n\nAll mothers will express milk using a hospital-grade breast pump, and the expression duration is standardized as 15 minutes per breast (30 minutes total) based on the literature. Two expressions will be performed - one before and one immediately after the intervention. Expressed milk will not be discarded and will instead be used to feed the babies via spoon or syringe under the researcher's supervision.",[26],[400,401,402,403,404],"breastmilk","mother","massage techniques","marmet technique","oxytocin massage","2025-09-16",{"date":407,"type":34},"2025-09-22",{"date":409,"type":34},"2025-08-25",{"date":411,"type":22},"2025-12-30",{"name":413,"class":41},"Ege University",{"id":415,"slug":416,"hasResults":11,"nctId":417,"briefTitle":418,"officialTitle":419,"acronym":420,"eligibilityCriteria":421,"healthyVolunteers":17,"sex":422,"minAge":19,"maxAge":105,"enrollmentInfo":423,"targetDuration":4,"studyType":53,"phases":425,"briefSummary":427,"conditions":428,"keywords":429,"overallStatus":88,"whyStopped":4,"lastUpdateSubmitDate":434,"lastUpdatePostDateStruct":435,"startDateStruct":437,"completionDateStruct":439,"leadSponsor":441,"locationsCount":42},"100600097","early-phase-1-the-effect-of-oral-oxytocin-and-atosiban-on-social-attention-100600097","NCT07093060","The Effect of Oral Oxytocin and Atosiban on Social Attention","The Influence and Regulatory Role of Exogenous and Endogenous Oxytocin on Social Attention in Humans","OTAtosiban","Inclusion Criteria:\n\n* Healthy male subjects without past or current psychiatric or neurological disorders\n\nExclusion Criteria:\n\n* History of or current neurological\u002Fpsychiatric disorders;\n* Use of psychotropic medications (including nicotine)\n* Visual impairments","MALE",{"count":424,"type":22},250,[426],"EARLY_PHASE1","The main aim of the present study is to investigate whether orally (lingual spray) administered oxytocin influences human social attention and behaviors via oxytocin receptors and whether its effects are dose- and task-dependent.",[26],[430,431,432,433],"Oxytocin","Atosiban","Eye tracking","Autistic trait","2025-07-28",{"date":436,"type":34},"2025-07-30",{"date":438,"type":34},"2025-06-09",{"date":440,"type":22},"2025-11-30",{"name":442,"class":41},"University of Electronic Science and Technology of China"]